BAM
ARKG icon

Belpointe Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Belpointe Asset Management’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,869
Closed -$340K – 922
2024
Q4 		$340K Sell
12,869
-8
-0.1% -$197 0.02% 615
2024
Q3 		$330K Buy
12,877
+3,409
+36% +$86.8K 0.02% 637
2024
Q2 		$222K Buy
9,468
+1,826
+24% +$46.1K 0.02% 688
2024
Q1 		$220K Buy
+7,642
New +$230K 0.02% 709
2023
Q2 		– Sell
-21,610
Closed -$650K – 749
2023
Q1 		$650K Sell
21,610
-33,623
-61% -$1.04M 0.04% 454
2022
Q4 		$1.56M Buy
55,233
+25,235
+84% +$801K 0.09% 221
2022
Q3 		$986K Buy
+29,998
New +$1.1M 0.07% 297
2022
Q2 		– Sell
-4,462
Closed -$206K – 1137
2022
Q1 		$206K Sell
4,462
-464
-9% -$22.1K 0.01% 894
2021
Q4 		$302K Sell
4,926
-234
-5% -$16.2K 0.02% 707
2021
Q3 		$385K Sell
5,160
-3,339
-39% -$280K 0.03% 594
2021
Q2 		$787K Buy
8,499
+3,722
+78% +$316K 0.06% 353
2021
Q1 		$424K Sell
4,777
-4,009
-46% -$398K 0.04% 483
2020
Q4 		$819K Buy
+8,786
New +$700K 0.07% 290

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Belpointe Asset Management's ARKG Position: Q1 2025 in Review

Belpointe Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2025, closing a stake of 12,869 shares — an estimated $340K sold.

Belpointe Asset Management first reported a position in ARKG in Q4 2020 and held it in 13 quarters. The position peaked at $1.56M in Q4 2022. 214 funds tracked by Wall St. Rank hold ARKG as of Q1 2025.

  • Belpointe Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2025 after selling out during the quarter.
  • Belpointe Asset Management sold 12,869 ARK Genomic Revolution ETF shares in Q1 2025, an estimated $340K.
  • Belpointe Asset Management first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 13 quarters.
  • Belpointe Asset Management's ARK Genomic Revolution ETF position peaked at $1.56M in Q4 2022.
  • 214 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2025.

Based on Belpointe Asset Management's 13F filing for Q1 2025, filed 20 May 2025.